SM
XERS icon

Sciencast Management’s Xeris Biopharma Holdings XERS Stock Holding History

Sciencast Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-35,934
Closed -$92K – 699
2022
Q1 		$92K Buy
+35,934
New +$87.8K 0.02% 474

Other funds holding XERS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Sciencast Management's XERS Position: Q2 2022 in Review

Sciencast Management sold out of Xeris Biopharma Holdings (XERS) in Q2 2022, closing a stake of 35,934 shares — an estimated $92K sold.

Sciencast Management first reported a position in XERS in Q1 2022 and held it in 1 quarter. The position peaked at $92K in Q1 2022. 103 funds tracked by Wall St. Rank hold XERS as of Q2 2022.

  • Sciencast Management reported no remaining Xeris Biopharma Holdings position as of Q2 2022 after selling out during the quarter.
  • Sciencast Management sold 35,934 Xeris Biopharma Holdings shares in Q2 2022, an estimated $92K.
  • Sciencast Management first reported a position in Xeris Biopharma Holdings in Q1 2022 and held it in 1 quarter.
  • Sciencast Management's Xeris Biopharma Holdings position peaked at $92K in Q1 2022.
  • 103 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2022.

Based on Sciencast Management's 13F filing for Q2 2022, filed 3 Aug 2022.